Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

GENE - CHEMICAL INTERACTIONS REPORT

RGD ID: 2199
Species: Rattus norvegicus
RGD Object: Gene
Symbol: Bcl2
Name: BCL2, apoptosis regulator
Acc ID: CHEBI:28680
Term: cytarabine
Definition: A pyrimidine nucleoside in which cytosine is attached to D-arabinofuranose via a beta-N(1)-glycosidic bond. Used mainly in the treatment of leukaemia, especially acute non-lymphoblastic leukaemia, cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. It also has antiviral and immunosuppressant properties.
Chemical ID: MESH:D003561
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction is comprised of a complex set of reactions and/or regulatory events, possibly involving additional chemicals and/or gene products.
Object SymbolQualifierEvidenceWithReferenceSourceNotesOriginal Reference(s)
Bcl2decreases expressionISOBCL2 (Homo sapiens)6480464CTDCytarabine results in decreased expression of BCL2 mRNA; Cytarabine results in decreased expression of BCL2 proteinPMID:1450413 PMID:16129037 PMID:17490525 PMID:9295281
Bcl2increases degradationISOBCL2 (Homo sapiens)6480464CTDCytarabine results in increased degradation of BCL2 proteinPMID:12853972
Bcl2multiple interactionsISOBCL2 (Homo sapiens)6480464CTD[Doxorubicin co-treated with Dexamethasone co-treated with Vincristine co-treated with Cytarabine co-treated with Mercaptopurine co-treated with Methotrexate co-treated with Cyclophosphamide co-treated with Enzymes and Coenzymes] results in increased expression of BCL2 protein; BCL2 protein inhibits the reaction [Cytarabine results in increased cleavage of and results in increased activity of CASP3 protein]; BCL2 protein inhibits the reaction [Cytarabine results in increased degradation of PARP1 protein]; edelfosine promotes the reaction [Cytarabine results in decreased expression of BCL2 protein]PMID:21182165 PMID:8840993 PMID:9295281
Go Back to source page   Continue to Ontology report